Association between circulating tumor DNA and the prognosis of solid tumor patients receiving neoadjuvant therapy: a meta-analysis
Circulating tumor DNA (ctDNA) has emerged as a promising noninvasive biomarker in solid tumors, yet its prognostic value following neoadjuvant therapy (NAT) warrants systematic validation. This study systematically searched databases such as PubMed, Embase, and the Cochrane Library, with a search period ra...